2006
Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation
TRBUŠEK, Martin, Jitka MALČÍKOVÁ, Jana ŠMARDOVÁ, Viera KUHROVÁ, Dita MENTZLOVÁ et. al.Základní údaje
Originální název
Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation
Název česky
Inaktivace p53 a delece ATM u B-CLL pacientů ve vztahu s IgVH
Autoři
TRBUŠEK, Martin (203 Česká republika, garant), Jitka MALČÍKOVÁ (203 Česká republika), Jana ŠMARDOVÁ (203 Česká republika), Viera KUHROVÁ (203 Česká republika), Dita MENTZLOVÁ (203 Česká republika), Soňa BUKOVSKÁ (203 Česká republika), Petr KUGLÍK (203 Česká republika), Michael DOUBEK (203 Česká republika), Yvona BRYCHTOVÁ (203 Česká republika), Šárka POSPÍŠILOVÁ (203 Česká republika), Dana DVOŘÁKOVÁ (203 Česká republika), Jiří VORLÍČEK (203 Česká republika), Jiří MAYER (203 Česká republika), Miluše SVITÁKOVÁ (203 Česká republika), Věra LINKOVÁ (203 Česká republika), Jiří ZAČAL (203 Česká republika) a Jitka KUJÍČKOVÁ (203 Česká republika)
Vydání
Leukemia, 2006, 0887-6924
Další údaje
Jazyk
angličtina
Typ výsledku
Článek v odborném periodiku
Obor
30200 3.2 Clinical medicine
Stát vydavatele
Velká Británie a Severní Irsko
Utajení
není předmětem státního či obchodního tajemství
Impakt faktor
Impact factor: 6.146
Kód RIV
RIV/00216224:14110/06:00019161
Organizační jednotka
Lékařská fakulta
UT WoS
000237806500035
Klíčová slova anglicky
B-CLL FASAY IgVH p53 ATM previous treatment
Příznaky
Mezinárodní význam, Recenzováno
Změněno: 26. 7. 2010 13:20, RNDr. Jitka Malčíková, Ph.D.
V originále
Defects in either of the two cooperating tumor suppressors, p53 or ATM, confer an inferior prognosis for B CLL patients. The abnormalities were reported to be associated with the unmutated IgVH subtype and may thus arise as a consequence of its more aggressive behaviour. However a recent report has also clearly correlated the p53 inactivation to a DNA damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003, 10: 477 to 484). We performed a comprehensive determination of p53 status in 168 B CLL samples (including functional FASAY analysis) and a deletion screening of ATM locus in 69% of the corresponding samples and correlated the data to the IgVH mutation status and to previous treatment. Inactivation of the p53 (overall frequency 12%) occurred markedly more frequently (P 0.05) and deletions of ATM (overall frequency 18%) strictly (P 0.001) in the unmutated IgVH subtype. A statistically significant correlation was not achieved between the presence of previous treatment (including alkylating agents in 44/49 cases) and the p53 or ATM abnormalities. In the IgVH unmutated subgroup, where the treatment was markedly more frequent, the proportion of the defects was similar in untreated/treated groups of patients. The p53/ATM inactivation does not seem to be primarily a consequence of DNA damaging chemotherapy.
Česky
Defects in either of the two cooperating tumor suppressors, p53 or ATM, confer an inferior prognosis for B CLL patients. The abnormalities were reported to be associated with the unmutated IgVH subtype and may thus arise as a consequence of its more aggressive behaviour. However a recent report has also clearly correlated the p53 inactivation to a DNA damaging chemotherapy including alkylating agents (Sturm et al., Cell Death Differ 2003, 10: 477 to 484). We performed a comprehensive determination of p53 status in 168 B CLL samples (including functional FASAY analysis) and a deletion screening of ATM locus in 69% of the corresponding samples and correlated the data to the IgVH mutation status and to previous treatment. Inactivation of the p53 (overall frequency 12%) occurred markedly more frequently (P 0.05) and deletions of ATM (overall frequency 18%) strictly (P 0.001) in the unmutated IgVH subtype. A statistically significant correlation was not achieved between the presence of previous treatment (including alkylating agents in 44/49 cases) and the p53 or ATM abnormalities. In the IgVH unmutated subgroup, where the treatment was markedly more frequent, the proportion of the defects was similar in untreated/treated groups of patients. The p53/ATM inactivation does not seem to be primarily a consequence of DNA damaging chemotherapy.
Návaznosti
| NR8445, projekt VaV |
| |
| NR8448, projekt VaV |
|